VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE · Real-Time Price · USD
0.4100
+0.0060 (1.49%)
Dec 11, 2025, 2:06 PM EST - Market open
VYNE Therapeutics Stock Forecast
Stock Price Forecast
There have not been any analyst price target forecasts for VYNE Therapeutics in the last 12 months.
Price Target: n/a
Analyst Consensus: Hold
Analyst Ratings
According to 1 stock analyst, the rating for VYNE Therapeutics is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jul 30, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5.75 → $4.5 | Strong Buy | Maintains | $5.75 → $4.5 | +997.56% | Apr 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5.75 | Strong Buy | Reiterates | $5.75 | +1,302.44% | Mar 6, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5.75 | Strong Buy | Reiterates | $5.75 | +1,302.44% | Feb 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5.75 | Strong Buy | Reiterates | $5.75 | +1,302.44% | Jan 14, 2025 |
Financial Forecast
Revenue This Year
306.00K
from 501.00K
Decreased by -38.92%
Revenue Next Year
357.00K
from 306.00K
Increased by 16.67%
EPS This Year
-0.81
from -0.94
EPS Next Year
-0.93
from -0.81
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 630,000 | 735,000 | ||||
| Avg | 306,000 | 357,000 | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 25.7% | 140.2% | ||||
| Avg | -38.9% | 16.7% | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.72 | -0.77 | ||||
| Avg | -0.81 | -0.93 | ||||
| Low | -0.87 | -1.08 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.